A fusion protein of hFGF21 or its analogs having improved pharmaceutical properties, and use of the fusion protein in preparing medicines for treating diseases, such as diabetes, obesity, non-alcoholic fatty liver disease, dyslipidemia, and/or metabolic syndrome.

The present invention provides a compound for the sequestration of undesirable antibodies (e.g. related to an autoimmune disease) in a patient. The compound comprises an inert biopolymer scaffold and at least a first peptide n-mer of the general formula P(-S-P).sub.(n-1) and a second peptide n-mer of the general formula P(-S-P).sub.(n-1); wherein, independently for each occurrence, P is a peptide with a sequence length of 2-13 amino acids and S is a non-peptide spacer, wherein, independently for each of the peptide n-mers, n is an integer of at least 1, wherein each of the peptide n-mers is bound to the biopolymer scaffold. Also provided are pharmaceutical compositions comprising the compound, as well as a method of sequestering one or more antibodies present in an individual and a method of inhibiting an immune reaction to a treatment with an active agent.

The invention provides a novel class of clearable, tumor-targeting and human protein-based MRI nanoprobes and contrast agents and their compositions, and methods of preparation and use thereof.

The present invention relates to a ferritin nanocage for multi-displaying a TRAIL trimer and a cancer-targeting peptide, and use thereof as an anticancer agent, and relates to the development of a TRAIL fusion nanoprotein, in which TRAIL with a trimer structure is conjugated to a human ferritin monomer fragment, and which exhibits enhanced cancer targeting using a cancer-targeting peptide. When injected into a blood vessel, the fusion protein according to the present invention effectively targets cancer and thus effectively leads to cancer death caused by TRAIL, wherein the fusion nanoprotein addresses the instability and off-targeting problems of TRAIL proteins, stably delivers a TRAIL trimer to cancer tissue, and thus there is a high possibility of developing an anticancer agent using same.

The present invention relates to a ferritin nanocage for multi-displaying a TRAIL trimer and a cancer-targeting peptide, and use thereof as an anticancer agent, and relates to the development of a TRAIL fusion nanoprotein, in which TRAIL with a trimer structure is conjugated to a human ferritin monomer fragment, and which exhibits enhanced cancer targeting using a cancer-targeting peptide. When injected into a blood vessel, the fusion protein according to the present invention effectively targets cancer and thus effectively leads to cancer death caused by TRAIL, wherein the fusion nanoprotein addresses the instability and off-targeting problems of TRAIL proteins, stably delivers a TRAIL trimer to cancer tissue, and thus there is a high possibility of developing an anticancer agent using same.

The present disclosure provides transferring receptor binding polypeptides of the general formula H1-H2-E1-H3-E2-E3-H-4, herein H1, H2, H3, and H4 each independently comprise an alpha, helical domain of between 11-20 amino acids in length; E1, E2, and E3 each independently comprise a beta sheet of 5 amino acids in length; and optional amino acid linkers between domains.

The present disclosure provides transferring receptor binding polypeptides of the general formula H1-H2-E1-H3-E2-E3-H-4, herein H1, H2, H3, and H4 each independently comprise an alpha, helical domain of between 11-20 amino acids in length; E1, E2, and E3 each independently comprise a beta sheet of 5 amino acids in length; and optional amino acid linkers between domains.

Pharmaceutical compositions containing transferrin and, or lactoferrin for use in promoting and or inducing the generation new neural cells in a patient that has suffered a neurodegenerative event arising from at least one of a traumatic brain injury, a non-traumatic brain injury, a spinal cord injury, a peripheral nerve injury, or peripheral neuropathy. Ideally, the transferrin and/or lactoferrin have a low iron saturation.

Pharmaceutical compositions containing transferrin and, or lactoferrin for use in promoting and or inducing the generation new neural cells in a patient that has suffered a neurodegenerative event arising from at least one of a traumatic brain injury, a non-traumatic brain injury, a spinal cord injury, a peripheral nerve injury, or peripheral neuropathy. Ideally, the transferrin and/or lactoferrin have a low iron saturation.

Disclosed are therapeutic payloads comprising p97 fragments coupled with active agents having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, to facilitate delivery of therapeutic or diagnostic agents across the BBB. The therapeutic payloads have dual functionality that may permit treatment of diseases in a subject other than diseases that present in the brain, e.g., solid tumors in the body. Methods of treating various diseases and pharmaceutical compositions are also disclosed.